Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/34872| Title: | Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision. | Austin Authors: | Mackintosh, John A;Keir, Gregory;Troy, Lauren K;Holland, Anne E ;Grainge, Christopher;Chambers, Daniel C;Sandford, Debra;Jo, Helen E;Glaspole, Ian;Wilsher, Margaret;Goh, Nicole S L ;Reynolds, Paul N;Chapman, Sally;Mutsaers, Steven E;de Boer, Sally;Webster, Susanne;Moodley, Yuben;Corte, Tamera J | Affiliation: | Department of Respiratory Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.;Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia. Department of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia. Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.;University of Sydney, Sydney, New South Wales, Australia. Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.;Department of Physiotherapy, The Alfred Hospital, Melbourne, Victoria, Australia.;Department of Respiratory Research@Alfred, Central Clinical School, Monash University, Melbourne, Victoria, Australia. Department of Respiratory Medicine, John Hunter Hospital, Newcastle, New South Wales, Australia. Department of Respiratory Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.;Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia. Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.;Department of Thoracic Medicine, Central Adelaide Local Health Network, Adelaide, South Australia, Australia.;University of Adelaide, Adelaide, South Australia, Australia. Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.;University of Sydney, Sydney, New South Wales, Australia. Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.;Department of Respiratory Medicine, The Alfred Hospital, Melbourne, Victoria, Australia. Department of Respiratory Medicine, Te Toka Tumai Auckland, Auckland, New Zealand. Respiratory and Sleep Medicine Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.;Department of Thoracic Medicine, Central Adelaide Local Health Network, Adelaide, South Australia, Australia.;University of Adelaide, Adelaide, South Australia, Australia. Institute for Respiratory Health, University of Western Australia, Nedlands, Western Australia, Australia. Department of Respiratory Medicine, Fiona Stanley Hospital, Murdoch, Western Australia, Australia. Department of Respiratory Medicine, Te Toka Tumai Auckland, Auckland, New Zealand. Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia. Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.;Institute for Respiratory Health, University of Western Australia, Nedlands, Western Australia, Australia.;Department of Respiratory Medicine, Fiona Stanley Hospital, Murdoch, Western Australia, Australia. ;Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.;University of Sydney, Sydney, New South Wales, Australia. |
Issue Date: | Feb-2024 | Date: | 2024 | Publication information: | Respirology (Carlton, Vic.) 2024-02; 29(2) | Abstract: | Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti-fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non-IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non-pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi-faceted approach to the management of IPF and progressive pulmonary fibrosis. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/34872 | DOI: | 10.1111/resp.14656 | ORCID: | 0000-0002-5254-4144 0000-0001-9979-8726 0000-0003-2061-845X 0000-0002-6565-9928 0000-0002-9553-5870 0000-0002-5118-2890 0000-0003-2046-8957 0000-0003-2065-4346 0000-0002-2273-1774 0000-0002-0777-1196 0000-0002-7096-9365 |
Journal: | Respirology (Carlton, Vic.) | PubMed URL: | 38211978 | ISSN: | 1440-1843 | Type: | Journal Article | Subjects: | idiopathic pulmonary fibrosis interstitial lung disease progressive pulmonary fibrosis pulmonary fibrosis treatment |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.